Canaccord Genuity analyst Sumant Kulkarni has maintained their bullish stance on NBIX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sumant Kulkarni has given his Buy rating due to a combination of factors related to Neurocrine’s current market performance and future potential. The company has demonstrated strong commercial execution with its two marketed products, Ingrezza and Crenessity, both of which have exceeded expectations. Crenessity’s launch has been particularly successful, driven by active engagement with key physician groups and a robust sales strategy.
Additionally, Ingrezza continues to perform well despite market uncertainties, and the company has shown confidence in its ability to meet sales projections. Looking ahead, Neurocrine’s pipeline is promising, with several exciting programs, including advancements in treatments for schizophrenia and major depressive disorder. The upcoming R&D Day is expected to further highlight the potential of these initiatives, reinforcing the company’s growth prospects and justifying the Buy rating.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $145.00 price target.